Bio-Rad Laboratories Inc. (BIO)
Bio-Rad Laboratories Statistics
Share Statistics
Bio-Rad Laboratories has 28.07M shares outstanding. The number of shares has increased by -1.66% in one year.
| Shares Outstanding | 28.07M |
| Shares Change (YoY) | -1.66% |
| Shares Change (QoQ) | 0.31% |
| Owned by Institutions (%) | 71% |
| Shares Floating | 23.49M |
| Failed to Deliver (FTD) Shares | 44 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.13M, so 4.03% of the outstanding shares have been sold short.
| Short Interest | 1.13M |
| Short % of Shares Out | 4.03% |
| Short % of Float | 6.5% |
| Short Ratio (days to cover) | 2.39 |
Valuation Ratios
The PE ratio is -5.03 and the forward PE ratio is 21.12. Bio-Rad Laboratories's PEG ratio is -0.03.
| PE Ratio | -5.03 |
| Forward PE | 21.12 |
| PS Ratio | 3.61 |
| Forward PS | 2.3 |
| PB Ratio | 1.41 |
| P/FCF Ratio | 34.82 |
| PEG Ratio | -0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Bio-Rad Laboratories.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.58 |
| Quick Ratio | 2.58 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.08 |
| Debt / FCF | 0.65 |
| Interest Coverage | 5.5 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $333.31K |
| Profits Per Employee | $-239.51K |
| Employee Count | 7,700 |
| Asset Turnover | 0.27 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -498.3M |
| Effective Tax Rate | 21.27% |
Stock Price Statistics
The stock price has increased by -11.13% in the last 52 weeks. The beta is 1.12, so Bio-Rad Laboratories's price volatility has been higher than the market average.
| Beta | 1.12 |
| 52-Week Price Change | -11.13% |
| 50-Day Moving Average | 251.32 |
| 200-Day Moving Average | 313.21 |
| Relative Strength Index (RSI) | 48.45 |
| Average Volume (20 Days) | 365.03K |
Income Statement
In the last 12 months, Bio-Rad Laboratories had revenue of 2.57B and earned -1.84B in profits. Earnings per share was -65.36.
| Revenue | 2.57B |
| Gross Profit | 1.38B |
| Operating Income | 269M |
| Net Income | -1.84B |
| EBITDA | -2.14B |
| EBIT | -2.29B |
| Earnings Per Share (EPS) | -65.36 |
Balance Sheet
The company has 488.1M in cash and 174.3M in debt, giving a net cash position of 313.8M.
| Cash & Cash Equivalents | 488.1M |
| Total Debt | 174.3M |
| Net Cash | 313.8M |
| Retained Earnings | 7.42B |
| Total Assets | 9.36B |
| Working Capital | 2.56B |
Cash Flow
In the last 12 months, operating cash flow was 455.2M and capital expenditures -189M, giving a free cash flow of 266.2M.
| Operating Cash Flow | 455.2M |
| Capital Expenditures | -189M |
| Free Cash Flow | 266.2M |
| FCF Per Share | 9.44 |
Margins
Gross margin is 53.73%, with operating and profit margins of 10.48% and -71.86%.
| Gross Margin | 53.73% |
| Operating Margin | 10.48% |
| Pretax Margin | -91.27% |
| Profit Margin | -71.86% |
| EBITDA Margin | -83.46% |
| EBIT Margin | 10.48% |
| FCF Margin | 10.37% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BIO is $417.5, which is 71.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $417.5 |
| Price Target Difference | 71.4% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Mar 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 1.23 |
| Piotroski F-Score | 6 |